- $725.62m
- $415.92m
- $14.02m
Annual cashflow statement for Immunome, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.4 | -17.8 | -24.7 | -36.9 | -107 |
| Depreciation | |||||
| Non-Cash Items | 0.017 | 6.16 | 2.95 | 5.54 | 103 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.212 | -1.21 | 2.78 | 2.24 | -3.98 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -9.6 | -12.1 | -18.2 | -28.7 | -7.57 |
| Capital Expenditures | -0.233 | -0.586 | -0.079 | -0.248 | -0.831 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | — | -29.7 |
| Sale of Business | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.233 | -0.586 | -0.079 | -0.248 | -30.5 |
| Financing Cash Flow Items | — | -5.97 | -0.781 | 0 | 116 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10.8 | 49.9 | 27.8 | 0.032 | 116 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.941 | 37.2 | 9.46 | -28.9 | 78.4 |